Prospective observation duration for each patient: at least 12 months (from enrollment)
Primary objective:~To obtain data pertaining to the safety and tolerability of alglucosidase alfa and laronidase treatments administered in a home-care infusion setting.~Secondary objectives:~To evaluate personal satisfaction of both cohorts of patients treated in a home-care infusion setting.~To evaluate the infusion compliance in both cohorts of patients treated in a home-care infusion setting.